Human medicines European public assessment report (EPAR): Nivestim, filgrastim, Date of authorisation: 07/06/2010, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Retacrit, epoetin zeta, Date of authorisation: 18/12/2007, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Lamzede, velmanase alfa, Date of authorisation: 23/03/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Fingolimod Accord, fingolimod, Date of authorisation: 25/06/2020, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Rasilez, aliskiren, Date of authorisation: 22/08/2007, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Pylclari, piflufolastat (18F), Date of authorisation: 27/11/2023, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Herceptin, trastuzumab, Date of authorisation: 28/08/2000, Revision: 47, Status: Authorised

One Health approach

Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - February 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 12 February 2026, 15:00 (CET) to 12 February 2026, 16:00 (CET)

European Medicines Agency (EMA) and European Alliance of Associations for Rheumatology (EULAR) bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, from 18 March 2026, 14:00 (CET) to 18 March 2026, 16:00 (CET)